Critical role of deoxynucleotidyl transferase terminal interacting protein 1 in oral cancer
出版年份 2018 全文链接
标题
Critical role of deoxynucleotidyl transferase terminal interacting protein 1 in oral cancer
作者
关键词
-
出版物
LABORATORY INVESTIGATION
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-05-31
DOI
10.1038/s41374-018-0070-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting Class I Histone Deacetylases in a “Complex” Environment
- (2017) Christopher J. Millard et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Long-term culture of human odontoma-derived cells with a Rho kinase inhibitor
- (2016) Katsuhiro Uzawa et al. EXPERIMENTAL CELL RESEARCH
- Understanding the Complexity of Epigenetic Target Space
- (2016) Vineet Pande JOURNAL OF MEDICINAL CHEMISTRY
- ARNT2 Regulates Tumoral Growth in Oral Squamous Cell Carcinoma
- (2016) Yasushi Kimura et al. Journal of Cancer
- The Effect of Resveratrol on Protecting Corneal Epithelial Cells from Cytotoxicity Caused by Moxifloxacin and Benzalkonium Chloride
- (2015) T.-Y. Tsai et al. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
- Cavin-2 in oral cancer: A potential predictor for tumor progression
- (2015) Motoharu Unozawa et al. MOLECULAR CARCINOGENESIS
- Structural and functional characterization of a cell cycle associated HDAC1/2 complex reveals the structural basis for complex assembly and nucleosome targeting
- (2015) Toshimasa Itoh et al. NUCLEIC ACIDS RESEARCH
- Semaphorin7A Promotion of Tumoral Growth and Metastasis in Human Oral Cancer by Regulation of G1 Cell Cycle and Matrix Metalloproteases: Possible Contribution to Tumoral Angiogenesis
- (2015) Tomoaki Saito et al. PLoS One
- Lipocalin-2 is associated with radioresistance in oral cancer and lung cancer cells
- (2013) MASASHI SHIIBA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Resveratrol as a Pan-HDAC Inhibitor Alters the Acetylation Status of Jistone Proteins in Human-Derived Hepatoblastoma Cells
- (2013) Sascha Venturelli et al. PLoS One
- Kinesin Family member 4A: A Potential Predictor for Progression of Human Oral Cancer
- (2013) Yasuyuki Minakawa et al. PLoS One
- Resveratrol Reduces Prostate Cancer Growth and Metastasis by Inhibiting the Akt/MicroRNA-21 Pathway
- (2012) Sandeep Sheth et al. PLoS One
- Dermatopontin: A potential predictor for metastasis of human oral cancer
- (2011) Masanobu Yamatoji et al. INTERNATIONAL JOURNAL OF CANCER
- Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma
- (2011) Christos Perisanidis et al. JOURNAL OF ORAL PATHOLOGY & MEDICINE
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
- (2011) Marcus Bantscheff et al. NATURE BIOTECHNOLOGY
- Phosphorylation of AIB1 at Mitosis Is Regulated by CDK1/CYCLIN B
- (2011) Macarena Ferrero et al. PLoS One
- Deficient Spindle Assembly Checkpoint in Multiple Myeloma
- (2011) Elena Díaz-Rodríguez et al. PLoS One
- Nutritional influences on epigenetics and age-related disease
- (2011) Lara K. Park et al. PROCEEDINGS OF THE NUTRITION SOCIETY
- Regulation of SIRT1 in cellular functions: Role of polyphenols
- (2010) Sangwoon Chung et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Epithelial Cell Transforming Sequence 2 in Human Oral Cancer
- (2010) Manabu Iyoda et al. PLoS One
- Terminal deoxynucleotidyl transferase: The story of a misguided DNA polymerase
- (2009) Edward A. Motea et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Histone Deacetylase Inhibition Activity and Molecular Docking of (E )-Resveratrol: Its Therapeutic Potential in Spinal Muscular Atrophy
- (2009) Didem Dayangaç-Erden et al. Chemical Biology & Drug Design
- HDAC expression and clinical prognosis in human malignancies
- (2008) Wilko Weichert CANCER LETTERS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More